Day 2

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

solaci
solaci
383
0

27_palacios_igor
Igor F. Palacios
2014-08-08

Director of Interventional Cardiology
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School

Previous article
Percutaneous Treatment of Mitral Regurgitation
Next article
Evaluation and Management of Asymptomatic Aortic Stenosis
solaci
solaci

More articles by this author

Hay Lugar Aun Para los Inhibidores GPIIbIIIa?

solaci - 0
Pedro Ureña Velásquez2014-08-08FACC FSCAI FACCPDirector Medicina Cardiovascular Asociada   

Thromboprophylaxis with antiplatelet agents in patients with mechanical aortic valves

solaci - 0
Raúl García-Rinaldo2014-08-08MD, PhD, FACS Ponce School of Medicine, Ponce, PRMayaguez Medical Center, Mayaguez, PR

Evaluation and Management of Asymptomatic Aortic Stenosis

solaci - 0
Augusto Pichard2014-08-08Director Innovation and Structural Heart Disease,  Vice Chair, Medstar Heart Institute, Medstar Washington Hospital Center. Professor of Medicine (Cardiology),Georgetown University Medical School.Washington, DC

Percutaneous Treatment of Mitral Regurgitation

solaci - 0
Igor F. Palacios2014-08-08Director of Interventional CardiologyMassachusetts General HospitalProfessor of MedicineHarvard Medical School

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 2

Hay Lugar Aun Para los Inhibidores GPIIbIIIa?

Pedro Ureña Velásquez2014-08-08FACC FSCAI FACCPDirector Medicina Cardiovascular Asociada   
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Dr. Juan Manuel Pérez - 0
Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Dr. Juan Manuel Pérez - 0
Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Dr. Juan Manuel Pérez - 0
Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...